Epilepsy Treatment Drugs Market Trends

Epilepsy Treatment Drugs Market Trends

• Growing awareness pertaining to epilepsy, its symptoms, and the importance of early diagnosis has led to a surge in patients seeking medical attention. Organizations such as the Epilepsy Foundation, Narayana Health, Epilepsy Society, and Epilepsy Association of Western & Central PA play a crucial role in promoting epilepsy education. The involvement of these organizations has resulted in increased rates of diagnosis and a broader patient population requiring epilepsy medications.
   
• Moreover, the increasing prevalence of epilepsy underscores the need for therapeutically effective medications, placing pressure on market players to introduce new antiepileptic drugs (AEDs). Despite the market availability of AEDs, approximately one-third of the population experiences drug intolerability. Thus, the manufacturers are actively emphasizing R&D to extend pipeline studies with targeted neuroscience to meet patient needs.
   
• For instance, in February 2023, Addex Therapeutics reported the completion of enrollment in Part 1 of the Phase 2 clinical study for ADX71149 (JNJ-40411813), intended for the treatment of epilepsy. ADX71149 functions as a selective positive allosteric modulator (PAM) of the metabotropic glutamate type 2 (mGlu2) receptor. Such R&D effort by players is expected to foster the market progress.